Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Psychiatric disorders and young adult milestones in HIV-exposed, uninfected youth.

Bucek A, Mellins CA, Leu CS, Dolezal C, Korich R, Wiznia A, Abrams EJ.

AIDS Care. 2019 Sep 19:1-9. doi: 10.1080/09540121.2019.1668535. [Epub ahead of print]

PMID:
31537111
2.

Sounding the Alarm: Perinatally HIV-Infected Youth More Likely to Attempt Suicide Than Their Uninfected Cohort Peers.

Kreniske P, Mellins CA, Dolezal C, Korich R, Leu CS, Wiznia A, Abrams EJ.

J Adolesc Health. 2019 Aug 31. pii: S1054-139X(19)30344-1. doi: 10.1016/j.jadohealth.2019.06.006. [Epub ahead of print]

PMID:
31481285
3.

Longitudinal trajectories of neurocognitive test performance among individuals with perinatal HIV-infection and -exposure: adolescence through young adulthood.

Robbins RN, Zimmerman R, Korich R, Raymond J, Dolezal C, Choi CJ, Leu CS, Nguyen N, Malee K, Wiznia A, Abrams EJ, Mellins CA.

AIDS Care. 2019 Jun 7:1-9. doi: 10.1080/09540121.2019.1626343. [Epub ahead of print]

PMID:
31174426
4.

Preliminary Validation of an Unannounced Telephone Pill Count Protocol to Measure Medication Adherence Among Young Adults With Perinatal HIV Infection.

Bucek A, Raymond J, Leu CS, Warne P, Abrams EJ, Dolezal C, Wiznia A, Kalichman S, Kalichman M, Mellins CA.

J Assoc Nurses AIDS Care. 2019 Apr 3. doi: 10.1097/JNC.0000000000000082. [Epub ahead of print]

PMID:
30958407
5.

Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.

Viani RM, Ruel T, Alvero C, Fenton T, Acosta EP, Hazra R, Townley E, Palumbo P, Buchanan AM, Vavro C, Singh R, Graham B, Anthony P, George K, Wiznia A; P1093 Study Team .

J Pediatric Infect Dis Soc. 2019 Apr 5. pii: piy139. doi: 10.1093/jpids/piy139. [Epub ahead of print]

PMID:
30951600
6.

Pediatric Asthma: A Global Epidemic.

Serebrisky D, Wiznia A.

Ann Glob Health. 2019 Jan 22;85(1). pii: 6. doi: 10.5334/aogh.2416. Review.

7.

Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.

Nachman S, Alvero C, Teppler H, Homony B, Rodgers AJ, Graham BL, Fenton T, Frenkel LM, Browning RS, Hazra R, Wiznia AA; IMPAACT 1066 study team.

Lancet HIV. 2018 Dec;5(12):e715-e722. doi: 10.1016/S2352-3018(18)30257-1.

8.

Behavioral Health and Adult Milestones in Young Adults With Perinatal HIV Infection or Exposure.

Abrams EJ, Mellins CA, Bucek A, Dolezal C, Raymond J, Wiznia A, Jurgrau A, Bamji M, Leu CS, Ng YKW.

Pediatrics. 2018 Sep;142(3). pii: e20180938. doi: 10.1542/peds.2018-0938. Epub 2018 Aug 10.

9.

Psychiatric Disorders, Antiretroviral Medication Adherence and Viremia in a Cohort of Perinatally HIV-Infected Adolescents and Young Adults.

Bucek A, Leu CS, Benson S, Warne P, Abrams EJ, Elkington KS, Dolezal C, Wiznia A, Mellins CA.

Pediatr Infect Dis J. 2018 Jul;37(7):673-677. doi: 10.1097/INF.0000000000001866.

10.

Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial.

Agwu AL, Warshaw MG, McFarland EJ, Siberry GK, Melvin AJ, Wiznia AA, Fairlie L, Boyd S, Harding P, Spiegel HML, Abrams EJ, Carey VJ; P1094 Study Team.

PLoS One. 2017 Jun 12;12(6):e0178075. doi: 10.1371/journal.pone.0178075. eCollection 2017.

11.

Association of Risk of Viremia, Immunosuppression, Serious Clinical Events, and Mortality With Increasing Age in Perinatally Human Immunodeficiency Virus-Infected Youth.

Neilan AM, Karalius B, Patel K, Van Dyke RB, Abzug MJ, Agwu AL, Williams PL, Purswani M, Kacanek D, Oleske JM, Burchett SK, Wiznia A, Chernoff M, Seage GR 3rd, Ciaranello AL; Pediatric HIV/AIDS Cohort Study and the International Maternal Adolescent and Pediatric AIDS Clinical Trials Network.

JAMA Pediatr. 2017 May 1;171(5):450-460. doi: 10.1001/jamapediatrics.2017.0141.

12.

Antiretroviral therapy in HIV-infected adolescents: clinical and pharmacologic challenges.

Dobroszycki J, Lee P, Romo DL, Rosenberg MG, Wiznia A, Abadi J.

Expert Rev Clin Pharmacol. 2017 May;10(5):509-516. doi: 10.1080/17512433.2017.1301205. Epub 2017 Mar 14. Review.

PMID:
28288535
13.

Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.

Tuluc F, Spitsin S, Tustin NB, Murray JB, Tustin R 3rd, Schankel LA, Wiznia A, Nachman S, Douglas SD.

AIDS Res Hum Retroviruses. 2017 Feb;33(2):133-142. doi: 10.1089/AID.2016.0108. Epub 2016 Oct 18.

14.

Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.

Cressey TR, Hazra R, Wiznia A, Foca M, Jean-Philippe P, Graham B, King JR, Britto P, Carey VJ, Acosta EP, Yogev R; IMPAACT P1058A Team.

Pediatr Infect Dis J. 2016 Dec;35(12):1333-1335.

15.

Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.

Larson KB, Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Acosta EP; International Maternal Pediatric and Adolescent AIDS Clinical Trial Protocol P1058A Team.

J Pediatric Infect Dis Soc. 2016 Jun;5(2):131-7. doi: 10.1093/jpids/piu142. Epub 2015 Jan 28.

16.

Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.

Foca M, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Britto P, Carey VJ, King J, Acosta EP, Cressey TR; IMPAACT P1058A Team.

Pediatr Infect Dis J. 2016 Sep;35(9):e271-4. doi: 10.1097/INF.0000000000001214.

17.

Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.

Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Fletcher CV, Acosta EP; IMPAACT P1058A Team.

J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):294-296. doi: 10.1093/jpids/piw017.

18.

Antiretroviral Drug Resistance Among Children and Youth in the United States With Perinatal HIV.

Van Dyke RB, Patel K, Kagan RM, Karalius B, Traite S, Meyer WA 3rd, Tassiopoulos KK, Seage GR 3rd, Seybolt LM, Burchett S, Hazra R; Pediatric HIV/AIDS Cohort Study (PHACS), Lurie RH, Yogev R, Sanders MA, Malee K, Hunter S, Shearer W, Paul M, Cooper N, Harris L, Purswani M, Baig M, Cintron A, Puga A, Navarro S, Garvie P, Blood J, Burchett S, Karthas N, Kammerer B, Wiznia A, Burey M, Nozyce M, Dieudonne A, Bettica L, Adubato S, Chen J, Bulkley MG, Ivey L, Grant M, Knapp K, Allison K, Wilkins M, Acevedo-Flores M, Rios H, Olivera V, Silio M, Jones M, Sirois P, Spector S, Norris K, Nichols S, McFarland E, Katai A, Dunn J, Paul S, Scott G, Bryan P, Willen E.

Clin Infect Dis. 2016 Jul 1;63(1):133-137. doi: 10.1093/cid/ciw213. Epub 2016 Apr 7.

19.

Patterns and Correlates of Serostatus Disclosure to Sexual Partners by Perinatally-Infected Adolescents and Young Adults.

Weintraub A, Mellins CA, Warne P, Dolezal C, Elkington K, Bucek A, Leu CS, Bamji M, Wiznia A, Abrams EJ.

AIDS Behav. 2017 Jan;21(1):129-140. doi: 10.1007/s10461-016-1337-6.

20.

Sexual Health Knowledge in a Sample of Perinatally HIV-infected and Perinatally-exposed Uninfected Youth.

Gromadzka O, Santamaria EK, Benavides JM, Dolezal C, Elkington KS, Leu CS, McKay M, Abrams EJ, Wiznia A, Bamji M, Ann Mellins C.

J HIV AIDS Soc Serv. 2015 Jul 1;14(3):277-293. Epub 2015 Aug 21.

21.

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.

Nachman S, Alvero C, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Rizk ML, Spector SA, Frenkel LM, Worrell C, Handelsman E, Wiznia A.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):e76-83. doi: 10.1093/jpids/piu146. Epub 2015 Feb 7.

22.

Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection.

Purswani MU, Karalius B, Yao TJ, Schmid DS, Burchett SK, Siberry GK, Patel K, Van Dyke RB, Yogev R; Pediatric HIV/AIDS Cohort Study (PHACS), Lurie RH, Yogev R, Sanders MA, Malee K, Hunter S, Shearer W, Paul M, Cooper N, Harris L, Purswani M, Baig M, Cintron A, Puga A, Navarro S, Garvie P, Blood J, Burchett S, Karthas N, Kammerer B, Wiznia A, Burey M, Nozyce M, Dieudonne A, Bettica L, Adubato S, Chen J, Bulkley MG, Ivey L, Grant M, Knapp K, Allison K, Wilkins M, Acevedo-Flores M, Rios H, Olivera V, Silio M, Jones M, Sirois P, Spector S, Norris K, Nichols S, McFarland E, Katai A, Dunn J, Paul S, Scott G, Bryan P, Willen E.

Clin Infect Dis. 2016 Jan 1;62(1):106-114. doi: 10.1093/cid/civ734. Epub 2015 Sep 18.

23.

Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093.

Viani RM, Alvero C, Fenton T, Acosta EP, Hazra R, Townley E, Steimers D, Min S, Wiznia A; P1093 Study Team.

Pediatr Infect Dis J. 2015 Nov;34(11):1207-13. doi: 10.1097/INF.0000000000000848.

24.

Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.

Dehority W, Abadi J, Wiznia A, Viani RM.

Drugs. 2015 Sep;75(13):1483-97. doi: 10.1007/s40265-015-0446-2. Review.

PMID:
26242765
25.

CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States.

Fairlie L, Karalius B, Patel K, van Dyke RB, Hazra R, Hernán MA, Siberry GK, Seage GR 3rd, Agwu A, Wiznia A; Pediatric HIV AIDS Cohort Study (PHACS), The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT).

AIDS. 2015 Oct 23;29(16):2109-19. doi: 10.1097/QAD.0000000000000809.

26.

Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents.

Krogstad P, Patel K, Karalius B, Hazra R, Abzug MJ, Oleske J, Seage GR 3rd, Williams PL, Borkowsky W, Wiznia A, Pinto J, Van Dyke RB; Pediatric HIVAIDS Cohort Study, IMPAACT 219C, and NICHD International Site Development Initiative (NISDI) Investigators.

AIDS. 2015 Mar 27;29(6):683-93. doi: 10.1097/QAD.0000000000000598.

27.

Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age.

Rizk ML, Du L, Bennetto-Hood C, Wenning L, Teppler H, Homony B, Graham B, Fry C, Nachman S, Wiznia A, Worrell C, Smith B, Acosta EP.

J Clin Pharmacol. 2015 Jul;55(7):748-56. doi: 10.1002/jcph.493. Epub 2015 Apr 13.

28.

HIV treatment adherence measurement and reporting concordance in youth with perinatally acquired HIV infection and their caregivers.

Evans SD, Mellins CA, Leu CS, Warne P, Elkington KS, Dolezal C, Santamaria EK, Wiznia A, Bamji M, Jurgrau-Voulgari AS, Abrams EJ.

AIDS Patient Care STDS. 2015 Jan;29(1):43-51. doi: 10.1089/apc.2014.0058.

29.

Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1066 Study Team.

Clin Infect Dis. 2014 Feb;58(3):413-22. doi: 10.1093/cid/cit696. Epub 2013 Oct 21.

30.

HIV-1 drug resistance prevalence, drug susceptibility and variant characterization in the Jacobi Medical Center paediatric cohort, Bronx, NY, USA.

de Mulder M, York VA, Wiznia AA, Michaud HA, Nixon DF, Holguin A, Rosenberg MG.

HIV Med. 2014 Mar;15(3):135-43. doi: 10.1111/hiv.12089. Epub 2013 Sep 25.

31.

Use of nucleoside reverse transcriptase inhibitor-only regimens in HIV-infected children and adolescents.

Neely M, Rutstein R, Del Bianco G, Heresi G, Barton T, Wiznia A, Wiegand R, Wheeling T, Bohannon B, Dominguez K; LEGACY Consortium.

Pediatr Infect Dis J. 2013 Sep;32(9):e370-6. doi: 10.1097/INF.0b013e31828e8c09.

32.

Discordance between aeroallergen specific serum IgE and skin testing in children younger than 4 years.

de Vos G, Nazari R, Ferastraoaru D, Parikh P, Geliebter R, Pichardo Y, Wiznia A, Rosenstreich D.

Ann Allergy Asthma Immunol. 2013 Jun;110(6):438-43. doi: 10.1016/j.anai.2013.03.006. Epub 2013 Apr 11.

33.

T cells target APOBEC3 proteins in human immunodeficiency virus type 1-infected humans and simian immunodeficiency virus-infected Indian rhesus macaques.

Champiat S, Garrison KE, Raposo RA, Burwitz BJ, Reed J, Tandon R, York VA, Newman LP, Nimityongskul FA, Wilson NA, Almeida RR, Martin JN, Deeks SG, Rosenberg MG, Wiznia AA, Spotts GE, Pilcher CD, Hecht FM, Ostrowski MA, Sacha JB, Nixon DF.

J Virol. 2013 Jun;87(11):6073-80. doi: 10.1128/JVI.00579-12. Epub 2013 Mar 27.

34.

Impact of HIV-1 infection and pregnancy on maternal health: comparison between perinatally and behaviorally infected young women.

Munjal I, Dobroszycki J, Fakioglu E, Rosenberg MG, Wiznia AA, Katz M, Steiner A, Sansary J, Heo M, Abadi J.

Adolesc Health Med Ther. 2013 Feb 21;4:51-8. doi: 10.2147/AHMT.S39885. eCollection 2013.

35.

Fear of repeated injections in children younger than 4 years receiving subcutaneous allergy immunotherapy.

de Vos G, Shankar V, Nazari R, Kooragayalu S, Smith M, Wiznia A, Rosenstreich D.

Ann Allergy Asthma Immunol. 2012 Dec;109(6):465-9. doi: 10.1016/j.anai.2012.10.003. Erratum in: Ann Allergy Asthma Immunol. 2013 Mar;110(3):216.

36.

Peripheral CD8+ T-cell levels are decreased in atopic wheezing children aged less than 4 years.

de Vos G, Milush JM, Aaron J, Pichardo Y, York VA, Nazari R, Rosenstreich D, Nixon DF, Wiznia A.

J Investig Allergol Clin Immunol. 2012;22(6):442-4. No abstract available.

37.

Age-related expansion of Tim-3 expressing T cells in vertically HIV-1 infected children.

Tandon R, Giret MT, Sengupta D, York VA, Wiznia AA, Rosenberg MG, Kallas EG, Ndhlovu LC, Nixon DF.

PLoS One. 2012;7(9):e45733. doi: 10.1371/journal.pone.0045733. Epub 2012 Sep 24.

38.

Individual and contextual factors of sexual risk behavior in youth perinatally infected with HIV.

Elkington KS, Bauermeister JA, Robbins RN, Gromadzka O, Abrams EJ, Wiznia A, Bamji M, Mellins CA.

AIDS Patient Care STDS. 2012 Jul;26(7):411-22. doi: 10.1089/apc.2012.0005. Epub 2012 Jun 13.

39.

Prevalence and change in psychiatric disorders among perinatally HIV-infected and HIV-exposed youth.

Mellins CA, Elkington KS, Leu CS, Santamaria EK, Dolezal C, Wiznia A, Bamji M, Mckay MM, Abrams EJ.

AIDS Care. 2012;24(8):953-62. doi: 10.1080/09540121.2012.668174. Epub 2012 Apr 23.

40.

Association of differentiation state of CD4+ T cells and disease progression in HIV-1 perinatally infected children.

Sharp ER, Willberg CB, Kuebler PJ, Abadi J, Fennelly GJ, Dobroszycki J, Wiznia AA, Rosenberg MG, Nixon DF.

PLoS One. 2012;7(1):e29154. doi: 10.1371/journal.pone.0029154. Epub 2012 Jan 11.

41.

Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children.

Miller TI, Borkowsky W, DiMeglio LA, Dooley L, Geffner ME, Hazra R, McFarland EJ, Mendez AJ, Patel K, Siberry GK, Van Dyke RB, Worrell CJ, Jacobson DL; Pediatric HIV/AIDS Cohort Study (PHACS), Shearer W, Cooper N, Harris L, Purswani M, Baig M, Cintron A, Puga A, Navarro S, Patton D, Burchett S, Karthas N, Kammerer B, Yogev R, Malee K, Hunter S, Cagwin E, Wiznia A, Burey M, Nozyce M, Chen J, Gobs E, Grant M, Knapp K, Allison K, Garvie P, Acevedo-Flores M, Rios H, Olivera V, Silio M, Borne C, Sirois P, Spector S, Norris K, Nichols S, McFarland E, Barr E, Chambers C, Watson D, Messenger N, Belanger R, Dieudonne A, Bettica L, Adubato S, Scott G, Himic L, Willen E.

HIV Med. 2012 May;13(5):264-75. doi: 10.1111/j.1468-1293.2011.00970.x. Epub 2011 Dec 4.

42.

Monitoring of HIV type 1 DNA load and drug resistance in peripheral blood mononuclear cells during suppressive antiretroviral therapy does not predict virologic failure.

Beck IA, Jang M, McKernan-Mullin J, Bull M, Wagner T, Huang S, Song LY, Nachman S, Krogstad P, Eshleman SH, Wiznia A, Frenkel LM.

AIDS Res Hum Retroviruses. 2012 Aug;28(8):780-8. doi: 10.1089/AID.2011.0039. Epub 2012 Jan 27.

43.

Identification of human endogenous retrovirus-specific T cell responses in vertically HIV-1-infected subjects.

Tandon R, SenGupta D, Ndhlovu LC, Vieira RG, Jones RB, York VA, Vieira VA, Sharp ER, Wiznia AA, Ostrowski MA, Rosenberg MG, Nixon DF.

J Virol. 2011 Nov;85(21):11526-31. doi: 10.1128/JVI.05418-11. Epub 2011 Aug 31.

44.

Immunodominance of HIV-1 specific CD8+ T-cell responses is related to disease progression rate in vertically infected adolescents.

Sharp ER, Willberg CB, Kuebler PJ, Abadi J, Fennelly GJ, Dobroszycki J, Wiznia AA, Rosenberg MG, Nixon DF.

PLoS One. 2011;6(7):e21135. doi: 10.1371/journal.pone.0021135. Epub 2011 Jul 19.

45.

Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.

King JR, Yogev R, Jean-Philippe P, Graham B, Wiznia A, Britto P, Carey V, Hazra R, Acosta EP; P1058 Protocol Team.

Antimicrob Agents Chemother. 2011 Sep;55(9):4290-4. doi: 10.1128/AAC.01334-10. Epub 2011 Jun 13.

46.

Pregnancy in women with perinatally acquired HIV-infection: outcomes and challenges.

Phillips UK, Rosenberg MG, Dobroszycki J, Katz M, Sansary J, Golatt MA, Wiznia AA, Abadi J.

AIDS Care. 2011 Sep;23(9):1076-82. doi: 10.1080/09540121.2011.554643. Epub 2011 May 23.

47.

CD4+ lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption.

Siberry GK, Patel K, Van Dyke RB, Hazra R, Burchett SK, Spector SA, Paul ME, Read JS, Wiznia A, Seage GR 3rd; Pediatric HIV/AIDS Cohort Study(PHACS).

J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):223-9. doi: 10.1097/QAI.0b013e318218e068.

48.

"I feel like I'm carrying a weapon." Information and motivations related to sexual risk among girls with perinatally acquired HIV.

Marhefka SL, Valentin CR, Pinto RM, Demetriou N, Wiznia A, Mellins CA.

AIDS Care. 2011 Oct;23(10):1321-8. doi: 10.1080/09540121.2010.532536. Epub 2011 May 24.

49.

Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients.

Dobroszycki J, Abadi J, Wiznia AA, Rosenberg MG.

Adolesc Health Med Ther. 2011 Sep 14;2:85-93. doi: 10.2147/AHMT.S11177. eCollection 2011. Review.

50.

Decay kinetics of HIV-1 specific T cell responses in vertically HIV-1 exposed seronegative infants.

Holditch SJ, Eriksson EM, Tarosso LF, Kuebler PJ, Kallas EG, Nielsen EK, Wiznia AA, Rosenberg MG, Nixon DF.

Front Immunol. 2012 Jan 11;2:94. doi: 10.3389/fimmu.2011.00094. eCollection 2011.

Supplemental Content

Loading ...
Support Center